U.S. Supreme Court Decision in Food and Drug Administration (FDA) v. Alliance for Hippocratic Medicine (AHM)

WASHINGTON — Today, the U.S. Supreme Court released its decision in Food and Drug Administration (FDA), et al. v. the Alliance for Hippocratic Medicine (AHM) et al. regarding the Food and Drug Administration’s (FDA) decisions in 2016 and 2021 to loosen regulations of the abortion drug mifepristone and whether the challengers had standing to bring their case. The Court unanimously ruled that the challenger in the case, the Alliance for Hippocratic Medicine, did not have standing. The Court did not rule on whether or not the FDA had acted properly in removing previous safeguards. Because the decision is based on standing, the FDA regulations on mifepristone remain. According to the Guttmacher Institute, a research arm of the abortion industry, approximately 63% of all abortions are done using chemical abortion methods like mifepristone and misoprostol. Mifepristone is used in combination with misoprostol, a prostaglandin, to cause an abortion. Mifepristone blocks progesterone, leading to the death of the unborn baby, while the second drug, misoprostol, causes powerful, painful uterine contractions to expel the dead or dying baby. Under the Biden Administration, the FDA weakened the Risk Evaluation and Mitigation Strategy (REMS) requirements for the drug combination to allow it to be dispensed and even mailed by pharmacies.